MedPath

Clinical Evaluation of an Innovative Non-contact Optical Device for Skin Oxygenation Imaging

Not Applicable
Not yet recruiting
Conditions
Chronic Wounds
Obliterating Arteriopathy of the Lower Limbs
Interventions
Device: Oxygen saturation measurement using the IPAM device
Device: Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device
Registration Number
NCT05187676
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

According to international consensus, information on the level of skin oxygenation is necessary for the diagnostic management of chronic wounds. The measurement of transcutaneous partial oxygen pressure (or TcPO2, according to the acronym) is measurable with a medical device that uses a Clark electrode. Since the medical device in question is expensive and the measurement time-consuming (approximately 45 minutes per patient), the TcPO2 is only rarely accessible (in hospital medicine as in nursing homes) and is therefore not predominant in the clinical decision. The clinical decision is currently mainly based on the result of the ankle blood pressure measurement, which is readily available.

The main objective is to study, from the same skin surfaces (same localization of skin sites and same dimensions of each surface in cm²), in patients with cutaneous vascular disorders or chronic wounds, the relationship between (i) the transcutaneous oxygen saturation values (expressed as a percentage) by the innovative non-contact optical imaging device under study (IPAM, method to be validated) and (ii) the transcutaneous partial oxygen pressure values (TcPO2) (expressed in millimeters of mercury, mmHg) measured by the reference medical device (Périflux6000, gold standard).

Detailed Description

The InnovaTICs Dépendance project, funded by the Grand Region Is, aims to develop a medical device meeting the need to measure quickly and non-invasively the skin oxygen saturation. To do this, a device medical was developed by CRAN (Joint Research Unit of the University of Lorraine and CNRS); its industrial transfer was entrusted to the company SD Innovation to produce the VRPC device for "video-reconstruction of chronic wounds". The VRPC medical device makes it possible to measure skin oxygen saturation by an optical (atraumatic) and non-contact (non-invasive) method, more quickly than the current method proposes. The capacity of the VRPC device to measure in vivo variations in skin oxygen saturation was confirmed by carrying out measurements on healthy volunteers. The measured values made it possible to show that the VRPC device was able to detect the difference in skin oxygen saturation between the skin covering a "healthy" finger and the skin covering the same finger but after a tourniquet had been placed at the base of the first phalanx of the finger (data not published).

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Major,

  • Having signed the informed consent to participate in the clinical study

  • Compulsory affiliation to a social security scheme

  • Presenting at least one of the following two criteria:

    • Presence of a PAD at the stage of Chronic Critical Ischemia (CHF) of stage III or IV according to the classification of Leriche and Fontaine,
    • Presence of one (or more) chronic wound (s) of the lower limbs of the pressure sore or ulcer type.
Exclusion Criteria
  • Person referred to in Articles L. 1121-5, L1121-6, L. 1121-7 and L1121-8 of the Public Health Code.
  • Pregnant woman, parturient or nursing mother
  • Minor (non-emancipated)
  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Person of full age unable to express consent
  • Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L.3212-1 and L. 3213-1.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 deviceScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)Oxygen saturation measurement using the IPAM deviceScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
Primary Outcome Measures
NameTimeMethod
Linear regression between the skin oxygen saturation rate (ScO2) values and the Transcutaneous oxygen partial (TcPO2) pressure valuesThrough study completion, an average of 2 years

The relationship between TcPO2 and ScO2 measurements will be modeled

Secondary Outcome Measures
NameTimeMethod
Risk evaluation: redness will be evaluated on a scale from zero to tenThrough study completion, an average of 2 years

Skin reddening will be evaluated

Rate of clinical decision influenced by the IPAM deviceThrough study completion, an average of 2 years

Questionnaire about the impact of the IPAM measurement on the clinical decision

Variation coefficient of the IPAM measurement made 3 times in a row on 3 different skin sitesThrough study completion, an average of 2 years

Repeatability of the IPAM measurement made 3 times in a row on 3 different skin sites

Ergonomics evaluation in terms of physical and mind effortsThrough study completion, an average of 2 years

Using a scale already used for medical devices ergonomics evaluation, the ergonomics of the two devices will be compared

Skin surface accessible for measurement in square centimetersThrough study completion, an average of 2 years

Comparison of the mean skin surface on which skin oxygen saturation rate and TcPO2 may be measured by each of the two medical devices used fot his study

Duration of use in secondsThrough study completion, an average of 2 years

Comparison of the mean duration time for acquiring one measurement with each of the devices used in the study

Mosaicing software success rateThrough study completion, an average of 2 years

The mosaicing software will be evaluated on a 20s-duration video sequence

Trial Locations

Locations (1)

CHRU de Nancy

🇫🇷

Vandoeuvre-lès-Nancy, France

© Copyright 2025. All Rights Reserved by MedPath